Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fructose-2,6-bisphosphatase isozyme 3 (PFKFB3) is a bifunctional enzyme containing both kinase (PFK-2) and phosphatase (FBPase-2) domains that regulates the cellular concentration of fructose 2,6-bisphosphate, a key signaling molecule for glycolysis and gluconeogenesis[3][4][5]. The kinase domain synthesizes fructose 2,6-bisphosphate from fructose 6-phosphate and ATP, while the phosphatase domain degrades it. This regulation is crucial for metabolic switching in response to hormonal and energetic cues. PFKFB3 is notable for high kinase activity relative to phosphatase activity, especially in rapidly proliferating cells such as cancer cells, and is under active investigation as a target for anticancer therapies due to its role in driving the "Warburg effect" (aerobic glycolysis)[2][5]. Structural studies show that alterations in key residues affect bisphosphatase activity and are important in the regulation of this isozyme[2].
Inhibition of kinase domain to block fructose 2,6-bisphosphate synthesis and suppress glycolysis, especially in proliferating cancer cells[5]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fructose-2,6-bisphosphatase isozyme 3 (PFKFB3).